Discover
AMRX
Amneal Pharmaceuticals, Inc.
16.97
2 x 12.48
2 x 21.58
bid
ask
-
0.34
1.96%
2 @ 04:00 PM
16.71 -0.26 (1.53%)
| Ytd | 34.68% | |
| 1y | 106.70% |
16.73
day range
17.46
7.67
52 week range
17.86
| Open | 17.32 | Prev Close | 17.31 | Low | 16.73 | High | 17.46 | Mkt Cap | 5.42B |
| Vol | 1.58M | Avg Vol | 1.85M | EPS | 0.37 | P/E | 45.86 | Forward P/E | 15.11 |
| Beta | 1.32 | Short Ratio | 4.27 | Inst. Own | 52.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 13.99 | 200-d Avg | 12.68 | 1yr Est | 17.25 |
| Income Statement | |||
| Total Revenue | 722.52M | ||
| Revenues (USD) | 722.52M | ||
| Cost of Revenue | 402.41M | ||
| Gross Profit | 320.11M | ||
| Operating Expenses | 178.34M | ||
| Research and Development Expense | 38.38M | ||
| Selling, General and Administrative Expense | 138.86M | ||
| Operating Income | 141.77M | ||
| Interest Expense | 53.36M | ||
| Income Tax Expense | 2.18M | ||
| Net Income | 62.26M | ||
| Net Income Common Stock | 62.26M | ||
| Net Income Common Stock (USD) | 62.26M | ||
| Consolidated Income | 78.00M | ||
| Net Income to Non-Controlling Interests | 15.74M | ||
| Earnings per Basic Share | 0.20 | ||
| Earnings per Basic Share (USD) | 0.20 | ||
| Earnings per Diluted Share | 0.19 | ||
| Earning Before Interest & Taxes (EBIT) | 117.79M | ||
| Earning Before Interest & Taxes (USD) | 117.79M | ||
| Weighted Average Shares | 316.02M | ||
| Weighted Average Shares Diluted | 328.93M | ||
| Balance Sheet | |||
| Cash and Equivalents | 201.83M | ||
| Cash and Equivalents (USD) | 201.83M | ||
| Trade and Non-Trade Receivables | 851.37M | ||
| Current Assets | 1.80B | ||
| Property, Plant & Equipment Net | 558.76M | ||
| Total Assets | 3.54B | ||
| Debt Current | 21.49M | ||
| Total Debt | 2.70B | ||
| Current Liabilities | 728.05M | ||
| Debt Non-Current | 2.68B | ||
| Total Liabilities | 3.59B | ||
| Accumulated Retained Earnings (Deficit) | -472.75M | ||
| Accumulated Other Comprehensive Income | -112.15M | ||
| Shareholders Equity | -45.41M | ||
| Shareholders Equity (USD) | -45.41M | ||
| Assets Non-Current | 1.74B | ||
| Total Debt (USD) | 2.70B | ||
| Goodwill and Intangible Assets | 1.13B | ||
| Inventory | 641.62M | ||
| Liabilities Non-Current | 2.86B | ||
| Trade and Non-Trade Payables | 663.43M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 43.19M | ||
| Net Cash Flow from Financing | -59.05M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -108.53M | ||
| Capital Expenditure | -13.86M | ||
| Issuance (Purchase) of Equity Shares | 38.00K | ||
| Issuance (Repayment) of Debt Securities | -6.17M | ||
| Net Cash Flow from Investing | -21.71M | ||
| Net Cash Flow from Operations | -26.74M | ||
| Effect of Exchange Rate Changes on Cash | -1.02M | ||
| Share Based Compensation | 8.82M | ||